Stay updated on Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.

Latest updates to the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page
- CheckyesterdayChange DetectedUI and metadata updates include a glossary toggle, a new label 'Last Update Submitted that Met QC Criteria' for QC status, capitalization changes for 'No FEAR Act Data', and a new page revision indicator 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check8 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedAdded new study locations: Fujian, Gansu, Heilongjiang, Henan, Shandong, Sichuan, Tianjin Municipality, Zhejiang (China) and Gyeonggi-do, Seoul Teugbyeolsi (South Korea). Updated revision tag from v3.3.2 to v3.3.3.SummaryDifference1%

- Check58 days agoChange DetectedRevision tag updated from v3.3.1 to v3.3.2 on the page, with no changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.3.1 updated from v3.2.0.SummaryDifference0.0%

- Check73 days agoChange DetectedRemoved the government funding status notice warning of possible delays and limited inquiries. The notice related to site operations and not to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.